Evidence map›Paper›PMID 25917783›Full record

ArticleGastroenterology2015

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Guillaume Lassailly, Robert Caiazzo, David Buob, Marie Pigeyre, Hélène Verkindt, Julien Labreuche, Violeta Raverdy, Emmanuelle Leteurtre, Sébastien Dharancy, Alexandre Louvet and 4 more

6 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 302 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
302citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03341429 phase4completedstarted 2018, after this paper: background citation

BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery

Ran2018Enrolled70Registered outcomes18Posted comparisons0ConditionsObesityArmsLiraglutide Pen Injector [Saxenda], Placebo
Open the trial in the graph
NCT03536650 nacompletednot on this mapstarted 2017, after this paper: background citation

Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study

TypeinterventionalSponsorErasme University HospitalRan2017 to 2020Enrolled14ConditionsNASH - Nonalcoholic SteatohepatitisArmsDMR
NCT04282005 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Metabolic Surgery for the Treatment and Understanding of Non-Alcoholic Steato-Hepatitis (NASH): Weight-Dependent and Weight-Independent Effects

TypeinterventionalSponsorKing's College LondonRan2020 to 2022Enrolled28ConditionsNon-alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steato-Hepatitis (NASH)ArmsMetabolic/Bariatric surgery, Lifestyle and Diet
NCT05798702 naactive not recruitingnot on this mapstarted 2021, after this paper: background citation

Fibrosis Reduction in Non Alcoholic Steatohepatitis: the Effects of Weight Loss vs Metabolic Surgery

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2021 to 2026Enrolled20ConditionsNASH With Fibrosis, Weight Loss, Bariatric Surgery CandidateArmsroux -en-y- gastric bypass, intensive life style modification
NCT06097338 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF

TypeobservationalSponsorQianfoshan HospitalRan2023 to 2026Enrolled200ConditionsFatty Liver Disease, NonalcoholicArmsbariatric surgery (BS)
NCT06180928 unknown statusnot on this mapstarted 2024, after this paper: background citation

Short Term Outcome of Metabolic Associated Fatty Liver Disease (MAFLD) in Patients Undergoing Bariatric Surgery

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled50ConditionsMetabolic Associated Fatty Liver Disease, Bariatric Surgery Candidate
3 · Its place in the literature

Who cites it

302 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Laparoscopic sleeve gastrectomy altersScientific reports · 2021
    Trial
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Management of obesity in advanced chronic liver disease.JHEP reports : innovation in hepatology · 2026
    Review

242 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Guillaume LassaillyService d'Hépato-Gastroentérologie, Université Lille 2, France; Unité Inserm U 995, Université Lille 2, France.
Robert CaiazzoUnité Inserm U 1011, Services de, Université Lille 2, France; Chirurgie Endocrinienne, Université Lille 2, France.
David Buobd'Anatomie Pathologique, Université Lille 2, France.
Marie Pigeyrede Nutrition, CHRU de Lille, Université Lille 2, France.
Hélène VerkindtChirurgie Endocrinienne, Université Lille 2, France.
Julien LabreucheDepartment of Biostatistics, Université Lille 2, France.
Violeta RaverdyChirurgie Endocrinienne, Université Lille 2, France.
Emmanuelle Leteurtred'Anatomie Pathologique, Université Lille 2, France.
Sébastien DharancyService d'Hépato-Gastroentérologie, Université Lille 2, France; Unité Inserm U 995, Université Lille 2, France.
Alexandre LouvetService d'Hépato-Gastroentérologie, Université Lille 2, France; Unité Inserm U 995, Université Lille 2, France.
Monique Romonde Nutrition, CHRU de Lille, Université Lille 2, France.
Alain DuhamelDepartment of Biostatistics, Université Lille 2, France.
François PattouUnité Inserm U 1011, Services de, Université Lille 2, France; Chirurgie Endocrinienne, Université Lille 2, France. Electronic address: fpattou@univ-lille2.fr.
Philippe MathurinService d'Hépato-Gastroentérologie, Université Lille 2, France; Unité Inserm U 995, Université Lille 2, France. Electronic address: philippe.mathurin@chru-lille.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsThe effects of bariatric surgery in patients with nonalcoholic fatty liver disease (NASH) are not well established. We performed a prospective study to determine the biological and clinical effects of bariatric surgery in patients with NASH.

methodsFrom May 1994 through May 2013, one hundred and nine morbidly obese patients with biopsy-proven NASH underwent bariatric surgery at the University Hospital of Lille, France (the Lille Bariatric Cohort). Clinical, biological, and histologic data were collected before and 1 year after surgery.

resultsOne year after surgery, NASH had disappeared from 85% of the patients (95% confidence interval [CI]: 75.8%-92.2%). Compared with before surgery, patients had significant reductions in mean ± SD body mass index (BMI, from 49.3 ± 8.2 to 37.4 ± 7) and level of alanine aminotransferase (from 52.1 ± 25.7 IU/L to 25.1 ± 20 IU/L); mean levels of γ-glutamyltransferases were reduced from 51 IU/L before surgery (interquartile range [IQR], 34-87 IU/L) to 23 IU/L afterward (IQR, 14-33 IU/L) and mean insulin resistance index values were reduced from 3.6 ± 0.5 to 2.9 ± 0.5 (P < .01 for each comparison). NASH disappeared from a higher proportion of patients with mild NASH before surgery (94%) than severe NASH (70%) (P < .05) according to Brunt score. In histologic analysis, steatosis was detected in 60% of the tissue before surgery (IQR, 40%-80%) but only 10% 1 year after surgery (IQR, 2.5%-21.3%); the mean nonalcoholic fatty liver disease score was reduced from 5 (IQR, 4-5) to 1 (IQR, 1-2) (each P < .001). Hepatocellular ballooning was reduced in 84.2% of samples (n = 69; 95% CI: 74.4-91.3) and lobular inflammation in 67.1% (n = 55; 95% CI: 55.8-77.1). According to Metavir scores, fibrosis was reduced in 33.8% of patients (95% CI: 23.6%-45.2%). Patients whose NASH persisted 1 year after surgery (n = 12) had lost significantly less weight (change in BMI, 9.1 ± 1.5) than those without NASH (change in BMI, 12.3 ± 0.6) (P = .005). Patients who underwent laparoscopic gastric banding lost less weight (change in BMI, 6.4 ± 0.7) than those who underwent gastric bypass (change in BMI, 14.0 ± 0.5) (P < .0001), and a higher proportion had persistent NASH (30.4% vs 7.6% of those with gastric bypass; P = .015).

conclusionsBariatric surgery induced the disappearance of NASH from nearly 85% of patients and reduced the pathologic features of the disease after 1 year of follow-up. It could be a therapeutic option for appropriate morbidly obese patients with NASH who do not respond to lifestyle modifications. More studies are needed to determine the long-term effects of bariatric surgery in morbidly obese patients with NASH.

Indexed as

Body Mass IndexWeight LossAdultAlanine TransaminaseBariatric SurgeryFemaleFollow-Up StudiesFrancegamma-GlutamyltransferaseGastric BypassHumansInsulin ResistanceLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseAlanine Transaminasegamma-GlutamyltransferaseLAGBNAFLDObesityWeight-Reduction Surgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.